Fresenius SE & Co. KGaA, commonly referred to as Fresenius, is a global healthcare group headquartered in Bad Homburg, Germany. Founded in 1912, the company has established itself as a leader in the healthcare industry, with significant operations across Europe, North America, and Asia. Fresenius operates primarily in the fields of dialysis, hospital management, and medical devices, providing innovative solutions that enhance patient care. The company’s core offerings include dialysis products and services through Fresenius Medical Care, as well as pharmaceuticals and clinical nutrition via Fresenius Kabi. Known for its commitment to quality and patient-centric solutions, Fresenius has achieved notable milestones, including being a key player in the global dialysis market. With a strong market position and a reputation for excellence, Fresenius continues to drive advancements in healthcare, making a meaningful impact on patients' lives worldwide.
How does Fresenius's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fresenius's score of 69 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Fresenius reported total carbon emissions of approximately 4.2 billion kg CO2e, comprising 351 million kg CO2e from Scope 1, 164.8 million kg CO2e from Scope 2, and about 3.7 billion kg CO2e from Scope 3 emissions. This reflects a slight decrease from 2023, where total emissions were approximately 4.2 billion kg CO2e, with Scope 1 emissions at 344 million kg CO2e, Scope 2 at 215 million kg CO2e, and Scope 3 at about 3.7 billion kg CO2e. Fresenius has set ambitious climate commitments, aiming for a 50% reduction in absolute Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline. Additionally, the company is committed to achieving climate neutrality across all scopes by 2040. These targets are part of their broader sustainability strategy, which includes initiatives to enhance energy efficiency and reduce emissions throughout their operations. The emissions data is sourced directly from Fresenius SE & Co. KGaA, with no cascaded data from parent or related organizations. The company is actively working towards its reduction goals and has outlined specific strategies to meet these targets.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 521,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,013,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Fresenius's Scope 3 emissions, which increased by 1% last year and increased by approximately 1% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 44% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fresenius has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.